

# Cassandra M Hirsch

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3436631/publications.pdf>

Version: 2024-02-01

35  
papers

1,004  
citations

623734

14  
h-index

501196

28  
g-index

36  
all docs

36  
docs citations

36  
times ranked

1735  
citing authors

#	ARTICLE	IF	CITATIONS
1	Single-cell characterization of leukemic and non-leukemic immune repertoires in CD8+ T-cell large granular lymphocytic leukemia. <i>Nature Communications</i> , 2022, 13, 1981.	12.8	23
2	Reduced red blood cell surface level of Factor H as a mechanism underlying paroxysmal nocturnal hemoglobinuria. <i>Leukemia</i> , 2021, 35, 1176-1187.	7.2	4
3	Personalized Prediction Model to Risk Stratify Patients With Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , 2021, 39, 3737-3746.	1.6	90
4	Large granular lymphocytic leukemia coexists with myeloid clones and myelodysplastic syndrome. <i>Leukemia</i> , 2020, 34, 957-962.	7.2	32
5	5-formylcytosine and 5-hydroxymethyluracil as surrogate markers of TET2 and SF3B1 mutations in myelodysplastic syndrome, respectively. <i>Haematologica</i> , 2020, 105, e213-e215.	3.5	2
6	Distinctive and common features of moderate aplastic anaemia. <i>British Journal of Haematology</i> , 2020, 189, 967-975.	2.5	10
7	Invariant phenotype and molecular association of biallelic TET2 mutant myeloid neoplasia. <i>Blood Advances</i> , 2019, 3, 339-349.	5.2	36
8	Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes. <i>Blood Advances</i> , 2019, 3, 4228-4237.	5.2	34
9	Molecular pathogenesis of disease progression in MLL-rearranged AML. <i>Leukemia</i> , 2019, 33, 612-624.	7.2	26
10	<i>BCOR</i> and <i>BCORL1</i> mutations in myelodysplastic syndromes (MDS): clonal architecture and impact on outcomes. <i>Leukemia and Lymphoma</i> , 2019, 60, 1587-1590.	1.3	16
11	Geno-Clinical Model for the Diagnosis of Bone Marrow Myeloid Neoplasms. <i>Blood</i> , 2019, 134, 4238-4238.	1.4	2
12	Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1. <i>Blood Cancer Journal</i> , 2018, 8, 4.	6.2	43
13	Clinical features and treatment outcomes in large granular lymphocytic leukemia (LGLL). <i>Leukemia and Lymphoma</i> , 2018, 59, 416-422.	1.3	72
14	Rational management approach to pure red cell aplasia. <i>Haematologica</i> , 2018, 103, 221-230.	3.5	57
15	Germline loss-of-function SAMD9 and SAMD9L alterations in adult myelodysplastic syndromes. <i>Blood</i> , 2018, 132, 2309-2313.	1.4	38
16	Consequences of mutant TET2 on clonality and subclonal hierarchy. <i>Leukemia</i> , 2018, 32, 1751-1761.	7.2	54
17	Clonal PIGA mosaicism and dynamics in paroxysmal nocturnal hemoglobinuria. <i>Leukemia</i> , 2018, 32, 2507-2511.	7.2	11
18	Fanconi Anemia germline variants as susceptibility factors in aplastic anemia, MDS and AML. <i>Oncotarget</i> , 2018, 9, 2050-2057.	1.8	16

#	ARTICLE	IF	CITATIONS
19	Heterozygous CTC1 Variants in Acquired Bone Marrow Failure. <i>Blood</i> , 2018, 132, 3866-3866.	1.4	0
20	BRCA1 & BRCA2 Germline Variants Are Enriched in MDS/AML and Portend Higher Average Mutational Burden. <i>Blood</i> , 2018, 132, 4352-4352.	1.4	1
21	Analysis of Even a Limited Number of Genes Indicates a Strong Inherited Component in Otherwise Typical Sporadic MDS. <i>Blood</i> , 2018, 132, 3074-3074.	1.4	0
22	Differences in Genomic Patterns between African Americans and Whites with Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 1527-1527.	1.4	0
23	Molecular features of early onset adult myelodysplastic syndrome. <i>Haematologica</i> , 2017, 102, 1028-1034.	3.5	20
24	A myeloid tumor suppressor role for NOL3. <i>Journal of Experimental Medicine</i> , 2017, 214, 753-771.	8.5	8
25	Dynamics of clonal evolution in myelodysplastic syndromes. <i>Nature Genetics</i> , 2017, 49, 204-212.	21.4	348
26	Origins of myelodysplastic syndromes after aplastic anemia. <i>Blood</i> , 2017, 130, 1953-1957.	1.4	50
27	Extent and Clinical Implications of Subclonal Diversity in Paroxysmal Nocturnal Hemoglobinuria. <i>Blood</i> , 2017, 130, 779-779.	1.4	2
28	Subcutaneous Low Dose Alemtuzumab: Role As a Salvage Therapy in Immune -Mediated Marrow Failure Conditions. <i>Blood</i> , 2016, 128, 1505-1505.	1.4	1
29	Molecular and Immunophenotypic Characteristics of Adult Acute Leukemias of Ambiguous Lineage. <i>Blood</i> , 2016, 128, 1659-1659.	1.4	2
30	Genetic and Epigenetic Defects in the Autophagy Machinery in Myelodysplastic Syndromes. <i>Blood</i> , 2016, 128, 4301-4301.	1.4	2
31	BCOR and BCORL1 mutations in Myelodysplastic Syndromes (MDS): Clonal Architecture and Impact on Outcomes. <i>Blood</i> , 2016, 128, 4293-4293.	1.4	0
32	PHF6 - Somatic Mutations and Their Role in Pathophysiology of MDS and AML. <i>Blood</i> , 2015, 126, 1259-1259.	1.4	1
33	Impact of Eltrombopag on Expansion of Clones with Somatic Mutations in Refractory Aplastic Anemia. <i>Blood</i> , 2015, 126, 300-300.	1.4	3
34	Determinants of Phenotypic Commitment and Clonal Progression--Conclusions from the Study of Clonal Architecture in CMML. <i>Blood</i> , 2015, 126, 2848-2848.	1.4	0
35	Network-Based Analysis of Exome Sequencing Mutations Identifies Molecular Subtypes of Myelodysplastic Syndromes. <i>Blood</i> , 2015, 126, 611-611.	1.4	0